Luteolin-3-O-beta-D-glucuronide
Based on 1 publication(s) in Google Scholar
Luteolin-3-O-beta-D-glucuronide, a glucuronide derivative of Luteolin (HY-N0162), is found in the leaves of Rosmarinus officinalis L. Luteolin-3-O-beta-D-glucuronide inhibits nitrite production in macrophages and binds strongly to FYN kinase.
For research use only. We do not sell to patients.
- Purity: 99.02%
- CAS No.: 53527-42-7
- Formula: C21H18O12
- Molecular Weight:462.36
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Luteolin-3-O-beta-D-glucuronide
More
Biological Activity
Luteolin-3-O-beta-D-glucuronide binds to human FYN kinase via hydrogen bonding, van der Waals forces, and Coulomb interactions, and exhibits strong binding affinity[2].
Luteolin-3-O-beta-D-glucuronide exhibits favorable computational simulation characteristics of good solubility, synthesizability and non-toxicity, with no blood-brain barrier permeability and low intestinal absorption rate[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 53527-42-7
-
Appearance Solid
-
Molecular Weight 462.36
-
Formula C21H18O12
-
Color Light yellow to yellow
-
SMILES
O=C1C2=C(O)C=C(O)C=C2OC(C3=CC(O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)=C(O)C=C3)=C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
RHBDL2 drives lipid metabolic reprogramming in osteosarcoma via USP3-mediated deubiquitination of PPT1. [Abstract]2026 Apr 24;17(1):548. PMID: 42031733
Solvent & Solubility
DMSO : 100 mg/mL (216.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Miroddi M, et al. Rosmarinus officinalis L. as cause of contact dermatitis. Allergol Immunopathol (Madr). 2014;42(6):616-619. [Content Brief]
[2]. Agarwal V, et al. Structure-based identification and experimental evaluation of Oroxin A as a FYN kinase inhibitor. J Comput Aided Mol Des. 2025;39(2):120. Published 2025 Nov 10. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1628 mL | 10.8141 mL | 21.6282 mL | 54.0704 mL |
| 5 mM | 0.4326 mL | 2.1628 mL | 4.3256 mL | 10.8141 mL | |
| 10 mM | 0.2163 mL | 1.0814 mL | 2.1628 mL | 5.4070 mL | |
| 15 mM | 0.1442 mL | 0.7209 mL | 1.4419 mL | 3.6047 mL | |
| 20 mM | 0.1081 mL | 0.5407 mL | 1.0814 mL | 2.7035 mL | |
| 25 mM | 0.0865 mL | 0.4326 mL | 0.8651 mL | 2.1628 mL | |
| 30 mM | 0.0721 mL | 0.3605 mL | 0.7209 mL | 1.8023 mL | |
| 40 mM | 0.0541 mL | 0.2704 mL | 0.5407 mL | 1.3518 mL | |
| 50 mM | 0.0433 mL | 0.2163 mL | 0.4326 mL | 1.0814 mL | |
| 60 mM | 0.0360 mL | 0.1802 mL | 0.3605 mL | 0.9012 mL | |
| 80 mM | 0.0270 mL | 0.1352 mL | 0.2704 mL | 0.6759 mL | |
| 100 mM | 0.0216 mL | 0.1081 mL | 0.2163 mL | 0.5407 mL |